Transthyretin amyloid cardiomyopathy has long been treated as a condition of damage control — slowing an inevitable march of protein deposits through heart muscle. Evidence that an RNA interference therapy might actually reverse measurable amyloid burden in cardiac tissue rewrites that assumption, and has direct implications for how clinicians monitor and manage this increasingly recognized disease.
This retrospective post hoc analysis drew from participants in the UK arm of the HELIOS-B trial, all followed at the National Amyloidosis Centre with serial cardiovascular MRI at baseline and at one, two, and three years. The key imaging metric was extracellular volume mapping — a validated CMR technique that quantifies amyloid infiltration in myocardial tissue. The analysis assessed whether vutrisiran, an RNA interference agent that suppresses hepatic transthyretin synthesis, produced detectable changes not just in cardiac structure and function but in the tissue-level amyloid burden itself. The HELIOS-B trial had already met its primary endpoint on clinical outcomes; this sub-study interrogates the biological mechanism behind those benefits with high-resolution imaging data.
The significance of this analysis lies in its mechanistic depth. Most approved ATTR-CM therapies — including tafamidis — stabilize the TTR tetramer and slow new amyloid deposition without clearing existing deposits. RNA interference takes a different route, dramatically suppressing TTR production at the source, which in theory allows the body's clearance mechanisms to gradually reduce existing amyloid load. If CMR is capturing genuine regression rather than fluid redistribution or inflammatory changes, it would provide the first imaging-level evidence that cardiac amyloid is reversible with existing treatments. Key limitations include the retrospective, single-center, post hoc design with a relatively small cohort and no placebo CMR comparator arm, making causal inference difficult. ECV changes also require careful interpretation since edema and fibrosis can confound readings. Despite these caveats, the use of multiparametric CMR as a trial endpoint biomarker represents a methodological advance worth tracking.